Where Catalyst Pharmaceuticals Stands With Analysts
Portfolio Pulse from Benzinga Insights
Catalyst Pharmaceuticals (NASDAQ:CPRX) has received positive ratings from analysts in the last quarter, with 4 bullish and 1 somewhat bullish ratings. The average price target for the stock is $24.2, indicating an upside from its current price of $13.715. The average price target has increased by 10.0% over the past month.
July 21, 2023 | 4:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Catalyst Pharmaceuticals has received positive ratings from analysts, indicating potential growth in its stock price.
The bullish sentiment from analysts, along with the average price target indicating an upside from the current price, suggests that the stock price of Catalyst Pharmaceuticals may increase in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100